Navigation Links
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Date:2/23/2009

escalating doses of TB-402. It is anticipated that the study will conclude by the end of 2010.

Patrik De Haes, CEO of ThromboGenics, commented on today's news "We are very excited about the start of the Phase II trial for TB-402. Our work to date suggests that this novel agent could represent a major advance in anti-coagulant therapy, given our expectation that it will cause fewer unwanted bleeding events and will require no monitoring of patients. This combined with its ability to be used as a "one-off" treatment could make TB-402 the anti-coagulant of choice to prevent DVT in patients undergoing surgery. Given the size of the market opportunity for TB-402 and the sales reach that will be needed to engage with the potential prescribers of TB-402, it is our intention to seek a partner to undertake the later stage development and commercialisation of this exciting new agent."

Svein Mathisen, CEO of BioInvent, also commented, "The initiation of this Phase II trial is another successful step forward in the clinical development of our antibody product development portfolio. TB-402 addresses a broad market and has potentially significant advantages over existing anti-coagulants. We are hopeful it will have application in a number of clinical settings."

About Deep Vein Thrombosis (DVT)

DVT is caused when a blood clot forms in a deep vein, most commonly in the deep veins of the lower leg. DVT is a major public health issue and it is estimated that in the U.S. alone, more than 350,000 individuals are affected by DVT or pulmonary embolism (PE) each year. Moreover, DVT and PE together may be responsible for more than 100,000 deaths in the U.S. each year.(1)

It is estimated that by 2015, 1.4 million patients will undergo knee replacement and 600,000 patients will undergo hip replacement in the U.S. if current trends persist.(2) Patients undergoing hip replacement or knee surgery are p
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics N.V.: Business Update
2. ThromboGenics Announces Half Year Results 2008
3. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
4. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
5. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
6. ThromboGenics N.V. - Business Update
7. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
10. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational ... (OTCQB: ALQA). Alliqua is an emerging biomedical company ... serve the wound care market. , Free report ... Alliqua was restructured with a seasoned management team ... to become a leading provider of wound care ...
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the ... Detwiler as the new Director of Product Strategy. In ... clients as well as iLab sub-teams to guide in ... be to ensure that iLab provides the maximum possible ... advanced, user-friendly, and high-impact solution in the world. ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ... patient safety, clinical outcomes, and medication adherence. , ...
(Date:1/14/2014)... 14, 2014 Kerr Corporation, a leading manufacturer ... additional how-to information about dual arch impressions on its dental ... Arch Impressions,” the blog entry serves up a list of ... a step-by-step demonstration by Dr. David Little as he crafts ... Take 1 Advanced Rigid as the dual arch dental ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... May 21 The American Acne & Rosacea Society ... Month which will occur in June 2009. At the ... Rosso, DO, President, stated that National Acne Awareness Month ... the treatment of acne and to generate awareness for ...
... Inc. ("Sinobiopharma ", or "the Company") (OTC Bulletin ... has applied for two Chinese patents for its ... relaxant. The Company has applied to China,s State ... for Atracurium,s freeze-drying compounds (Application Number 200710127756.2; "Atracurium,s ...
... 20 InspireMD, Ltd. announced today,the completion of ... The trial was designed to confirm the clinical ... Primary PCI in STEMI,patients. , ... single arm, 60 patients,study (Principal investigator: Dr. Dariusz ...
Cached Biology Technology:American Acne & Rosacea Society Announces Acne Awareness Month - June 2009 2Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate 2InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le 2InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le 3
(Date:4/15/2014)... San Diego have succeeded in visualizing the movement ... growth and resistance to drought. The achievement will ... how the hormone helps plants respond to drought ... increase in the atmosphere,s carbon dioxide, or CO2, ... the April 15 issue of the scientific journal ...
(Date:4/15/2014)... of the loveliest in the world, but they also ... soils have become enriched in cadmium. Grasses take up ... the cattle and sheep that graze them. The problem ... reported worldwide. , The concern is that if cadmium ... products, human health and New Zealand,s agricultural economy could ...
(Date:4/15/2014)... the Congo Basin to increase by 0.7 C. ... gases by half, according to a study by ... Explosive population growth and inefficient agricultural practices are ... Africa. A team of researchers from the University ... longer-term temperatures in the region. Using a sophisticated ...
Breaking Biology News(10 mins):Biologists develop nanosensors to visualize movements and distribution of plant hormone 2Study: Deforestation could intensify climate change in Congo Basin by half 2
... ways in which cooperation is the theme of a paper ... scientists at the Marine Biological Laboratorys (MBL) Josephine Bay Paul ... where the Alliegros thank those who helped them after Hurricane ... in New Orleans and their lives in 2005. ...
... sophisticated unmanned aircraft, research scientists at Scripps Institution ... Southern Californias potential for climate change and better ... by the California Energy Commission, the California AUAV ... aerial vehicles (AUAVs) to gather meteorological data as ...
... a protein in the blood linked to defence ... previously understood in the bodys immune defence system. ... of how the body defends against disease and heals ... protein, Properdin discovered only half a century ago- can ...
Cached Biology News:The cooperative view: New evidence suggests a symbiogenetic origin for the centrosome 2Unmanned aircraft to study Southern California smog and its consequences 2Unmanned aircraft to study Southern California smog and its consequences 3New discovery on role of vital protein that fights meningitis 2
... is the industry standard microarray image analysis ... imaging and analysis tools, visualizations, automation capabilities, ... is included with every GenePix scanner, and ... scanners and all types of arrays. A ...
... one mouse-click image analysis software for ... is the solution for high quality ... MicroVigene is empowered with VigeneTechs robust ... regional 2D-curve fitting background correction and ...
... applications not requiring confocal, the BD Pathway ... the Pathway 435. And, the Pathway 415 ... applications require it. High-performance, ... to use the laser autofocus, camera autofocus, ...
... ProXPRESS 2D Proteomic Imaging System, Professional ... Over a Wide Dynamic Range: The ProXPRESS ... sensitive in imaging system for both proteomic ... 2D provides unparalleled flexibility, enabling the use ...
Biology Products: